News
ABIO
2.172
+3.41%
0.072
One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year
Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...
Simply Wall St. · 11/14 14:24
BRIEF-Arca Biopharma Announces Third Quarter 2022 Financial Results
Reuters · 10/28 20:32
ARCA biopharma GAAP EPS of -$0.16
Seekingalpha · 10/28 20:18
ARCA biopharma Q3 EPS $(0.16) Up From $(0.33) YoY
Benzinga · 10/28 20:16
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.16
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.16
MT Newswires · 10/28 16:36
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey
MT Newswires · 10/14 09:30
BRIEF-ARCA Biopharma Announces Q2 2022 Financial Results
BRIEF-ARCA Biopharma Announces Q2 2022 Financial Results
Reuters · 08/02 21:32
ARCA biopharma GAAP EPS of -$0.22
ARCA biopharma press release (NASDAQ:<a ...
Seekingalpha · 08/02 21:16
-- Earnings Flash (ABIO) ARCA BIOPHARMA Posts Q2 Loss $-0.22
-- Earnings Flash (ABIO) ARCA BIOPHARMA Posts Q2 Loss $-0.22
MT Newswires · 08/02 16:29
Is ARCA biopharma (NASDAQ:ABIO) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 07/18 10:14
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committ...
GlobeNewswire · 05/05 20:15
ARCA biopharma GAAP EPS of -$0.23
ARCA biopharma press release (NASDAQ:ABIO): Q1 GAAP EPS of -$0.23. Cash and cash equivalents were $49.1 million as of March 31, 2022, compared to $53.4 million as of December 31,
Seekingalpha · 05/02 20:57
BRIEF-Arca Biopharma Announces First Quarter 2022 Financial Results
reuters.com · 05/02 20:53
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q1 Loss $-0.23
MT Newswires · 05/02 16:26
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
Benzinga · 04/18 21:34
BRIEF-Arca Biopharma Establishes Special Committee Of The Board Of Directors
reuters.com · 04/18 20:50
ARCA biopharma establishes special board committee to evaluate strategic options
ARCA biopharma (NASDAQ:ABIO) on Monday established a special committee of its board of directors to evaluate strategic options for the biopharmaceutical company. ABIO did not specify what kind of options
Seekingalpha · 04/18 20:44
ARCA biopharma Reports Has Established Special Committee Of Board
ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors
Benzinga · 04/18 20:31
Arca Biopharma Board to Weigh Strategic Options for Company -- Shares Rise After-Hours
MT Newswires · 04/18 17:04
Albioma : Governance changes
Press release Paris La Défense, 5 April 2022 Governance changes Marie-Claire Daveu has informed Albioma today of her intention to resign from the Board of Directors with effect from 31 July 2022, with her appointment as Director to be submitted to Engie's ...
GlobeNewswire · 04/05 05:35
More
Webull provides a variety of real-time ABIO stock news. You can receive the latest news about Arca Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company, which is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro (bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. The gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201). Its ASPEN-COVID-19 Phase IIb is a randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin prescribed per local standard of care in hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level.